Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $52.33 Consensus Target Price from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has received a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $52.33.

AGIO has been the topic of a number of analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Scotiabank lifted their price objective on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Finally, Raymond James reiterated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $55.68 on Friday. The stock has a market capitalization of $3.18 billion, a P/E ratio of 4.90 and a beta of 0.75. Agios Pharmaceuticals has a 12-month low of $20.96 and a 12-month high of $62.58. The firm’s 50-day moving average is $47.42 and its two-hundred day moving average is $44.51.

Insider Activity

In other news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth about $37,000. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC boosted its holdings in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.